These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35680060)

  • 1. TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats.
    Zhao C; Hu L; He X; Li L; Yin M; Tettey AT; Wang Y; Shen J; Tang S; Wu C; Li Q; Wang Z; Li X
    Vascul Pharmacol; 2022 Aug; 145():107017. PubMed ID: 35680060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DYZY01 alleviates pulmonary hypertension via inhibiting endothelial cell pyroptosis and rescuing endothelial dysfunction.
    Dai X; Liu Y; Wu Y; Wang S; Guo Q; Feng X; Zhao F; Li Y; Lan L; Li X
    Eur J Pharmacol; 2024 Sep; 978():176785. PubMed ID: 38942262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats.
    Tang B; Chen GX; Liang MY; Yao JP; Wu ZK
    Int J Cardiol; 2015 Feb; 180():134-41. PubMed ID: 25438234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension.
    Lan B; Hayama E; Kawaguchi N; Furutani Y; Nakanishi T
    PLoS One; 2015; 10(1):e0117211. PubMed ID: 25629315
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 3,7-Bis(2-hydroxyethyl)icaritin, a potent inhibitor of phosphodiesterase-5, prevents monocrotaline-induced pulmonary arterial hypertension via NO/cGMP activation in rats.
    Lan TH; Chen XL; Wu YS; Qiu HL; Li JZ; Ruan XM; Xu DP; Lin DQ
    Eur J Pharmacol; 2018 Jun; 829():102-111. PubMed ID: 29665366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic interaction between a PDE5 inhibitor (sildenafil) and a new adenosine A2A receptor agonist (LASSBio-1359) improves pulmonary hypertension in rats.
    Alencar AK; Carvalho FI; Silva AM; Martinez ST; Calasans-Maia JA; Fraga CM; Barreiro EJ; Zapata-Sudo G; Sudo RT
    PLoS One; 2018; 13(4):e0195047. PubMed ID: 29677206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PRDX6-mediated pulmonary artery endothelial cell ferroptosis contributes to monocrotaline-induced pulmonary hypertension.
    Liao J; Xie SS; Deng Y; Wu DD; Meng H; Lan WF; Dai P
    Microvasc Res; 2023 Mar; 146():104471. PubMed ID: 36566948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
    Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
    Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydromyricetin prevents monocrotaline-induced pulmonary arterial hypertension in rats.
    Li Q; Wang J; Zhu X; Zeng Z; Wu X; Xu Y; Xie J; Yu J
    Biomed Pharmacother; 2017 Dec; 96():825-833. PubMed ID: 29078260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Single Drug and Combined Short-term Administration of Sildenafil, Pimobendan, and Nicorandil on Right Ventricular Function in Rats With Monocrotaline-induced Pulmonary Hypertension.
    Nakata TM; Tanaka R; Yoshiyuki R; Fukayama T; Goya S; Fukushima R
    J Cardiovasc Pharmacol; 2015 Jun; 65(6):640-8. PubMed ID: 25806612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension.
    Tang Y; Tan S; Li M; Tang Y; Xu X; Zhang Q; Fu Q; Tang M; He J; Zhang Y; Zheng Z; Peng J; Zhu T; Xie W
    BMC Pulm Med; 2022 Apr; 22(1):142. PubMed ID: 35413880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Additive effect of tadalafil and simvastatin on monocrotaline-induced pulmonary hypertension rats.
    Zhang WH; Liu CP; Zhang YJ; Ji YQ; Lu WX; Zeng Q
    Scand Cardiovasc J; 2012 Dec; 46(6):374-80. PubMed ID: 22971207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelial cell ferroptosis mediates monocrotaline-induced pulmonary hypertension in rats by modulating NLRP3 inflammasome activation.
    Xie SS; Deng Y; Guo SL; Li JQ; Zhou YC; Liao J; Wu DD; Lan WF
    Sci Rep; 2022 Feb; 12(1):3056. PubMed ID: 35197507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of aqueous extract of stem bark of Terminalia arjuna (Roxb.), An ayurvedic drug in experimental pulmonary hypertension.
    Meghwani H; Prabhakar P; Mohammed SA; Seth S; Hote MP; Banerjee SK; Arava S; Ray R; Maulik SK
    J Ethnopharmacol; 2017 Feb; 197():184-194. PubMed ID: 27401289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
    Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
    Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of masitinib compared with tadalafil for the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.
    Leong ZP; Hikasa Y
    Vascul Pharmacol; 2019; 122-123():106599. PubMed ID: 31629919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin, sildenafil and their combination in monocrotaline-induced pulmonary hypertension in rat.
    Jasińska-Stroschein M; Owczarek J; Wesołowska A; Orszulak-Michalak D
    Acta Pharm; 2014 Sep; 64(3):345-53. PubMed ID: 25296680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Puerarin-V prevents the progression of hypoxia- and monocrotaline-induced pulmonary hypertension in rodent models.
    Chen D; Zhang HF; Yuan TY; Sun SC; Wang RR; Wang SB; Fang LH; Lyu Y; Du GH
    Acta Pharmacol Sin; 2022 Sep; 43(9):2325-2339. PubMed ID: 35190697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sildenafil prevents and reverses transverse-tubule remodeling and Ca(2+) handling dysfunction in right ventricle failure induced by pulmonary artery hypertension.
    Xie YP; Chen B; Sanders P; Guo A; Li Y; Zimmerman K; Wang LC; Weiss RM; Grumbach IM; Anderson ME; Song LS
    Hypertension; 2012 Feb; 59(2):355-62. PubMed ID: 22203744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
    Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
    Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.